fluindione

Trade name: previscan

Small moleculeexperimental

Clinical trial activity

6 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
2

Earliest trial started Feb 1, 2003 (NCT00966290)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C1c2ccccc2C(=O)C1c1ccc(F)cc1
Mol. weight
240.23 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1h-indene-1,3(2h)-dione, 2-(4-fluorophenyl)-
  • 2-(4-fluorophenyl)-1,3-indanedione
  • fluindione
  • fluindione
  • fluindione
  • fluindione
  • fluindione
  • fluindione
  • fluindione
  • fluindione
  • previscan
  • previscan
  • previscan
  • previscan

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02981472Phase 2Jan 4, 2017Bristol-Myers Squibb, Pfizer
NCT01830543Phase 3May 1, 2013Bayer, Janssen Pharmaceutica NV, Johnson and Johnson
NCT02161965Phase 4May 1, 2013University of Angers, University of Antwerp
NCT01674647Phase 3Oct 1, 2012Bayer, Johnson and Johnson
NCT00067093Phase 3May 1, 2003Sanofi
NCT00966290Phase 4Feb 1, 2003Jean Monnet University, University of Toulouse
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BayerFor profit2112012
Johnson and JohnsonFor profit2112012
Bristol-Myers SquibbFor profit1112017
Janssen Pharmaceutica NVFor profit1012013
Jean Monnet UniversityAcademic/Hospital1012003
PfizerFor profit1012017
SanofiFor profit1112003
University of AngersAcademic/Hospital1012013
University of AntwerpAcademic/Hospital1112013
University of ToulouseAcademic/Hospital1112003
10 organizations
Page 1 / 1